Business Wire·Dec 11, 2025, 8:00 AM ET

Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

ADGM

Adagio Medical Holdings, Inc. appointed Sean Salmon to its Board of Directors, where he will serve on the Audit Committee & Compensation Committee.
Salmon retired from Medtronic after a 20+ year tenure, most recently serving as Executive Vice President & President of the Cardiovascular Portfolio.
He holds extensive expertise in electrophysiology therapies, including leading strategic initiatives such as the acquisition of Affera & approvals for Pulse Select & Sphere 9 pulsed field ablation catheters.
Salmon previously led Medtronic's Coronary & Structural Heart business, overseeing entry into the drug-eluting stent market & expansion of the TAVR franchise.
His career also includes serving as Executive Vice President & President of the Medtronic Diabetes Operating Unit & holding management roles at C.R. Bard, Johnson & Johnson, SurgiVision, & EuroRSCG Life.
Adagio CEO Todd Usen stated Salmon's broad EP experience & ability to commercialize breakthrough platforms will be invaluable to the Company's strategic priorities.
Adagio is developing its vCLAS™ Cryoablation System using proprietary Ultra-Low Temperature Cryoablation (ULTC) technology for treating ventricular arrhythmias.
The vCLAS™ system is CE Marked & commercially available in Europe & select geographies but is under investigational use in the U.S. via the FULCRUM-VT pivotal trial.
The FULCRUM-VT trial has fully enrolled 209 patients with structural heart disease & drug-refractory ventricular tachycardia to support FDA premarket approval.
The press release includes forward-looking statements regarding FDA approval, commercialization plans, & future operations subject to risks & uncertainties.